



Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

November 9, 2023

BOSTON--(BUSINESS WIRE)--Nov. 9, 2023-- [Astria Therapeutics, Inc.](#) (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215 and STAR-0310 at the Jefferies London Healthcare Conference on Wednesday, November 15, at 10:30am GMT in London, UK.

A webcast of the presentation can be accessed at the following link: <https://wsw.com/webcast/jeff287/atxs/1884032>. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231109732128/en/): <https://www.businesswire.com/news/home/20231109732128/en/>

Astria:

Investor Relations and Media:

Elizabeth Higgins

investors@astriatx.com

Source: Astria Therapeutics, Inc.